TRANSLATE BIO
Translate Bio is a biotechnology company that in biotechnology, RNA therapeutics, and rare diseases. Translate Bio is a therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
TRANSLATE BIO
Industry:
Biotechnology Genetics Medical Therapeutics
Founded:
2011-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.translate.bio
Total Employee:
101+
Status:
Closed
Contact:
(617) 945-7361
Email Addresses:
[email protected]
Total Funding:
442.63 M USD
Technology used in webpage:
SPF Amazon ASP.NET IIS IIS 10 Amazon Ohio Region NameBright Tierpoint
Similar Organizations
10X Genomics
10X Genomics ELV solutions and security systems company that provides an innovative genomics platform.
23andMe
23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Immunome
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery.
Kymera Therapeutics
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Micropep Technologies
Micropep Technologies is a biotech company that focused on biological alternatives to agrochemicals.
Vaxart
Vaxart is a biotechnology company that develops vaccine technology for the treatment of infectious diseases.
Zymeworks
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Omega Funds
Omega Funds investment in Series C - Translate Bio
The Baupost Group
The Baupost Group investment in Series C - Translate Bio
Fidelity
Fidelity investment in Series C - Translate Bio
The Baupost Group
The Baupost Group investment in Series C - Translate Bio
Fidelity
Fidelity investment in Series C - Translate Bio
Atlas Venture
Atlas Venture investment in Series C - Translate Bio
SR One
SR One investment in Series C - Translate Bio
MRL Ventures Fund
MRL Ventures Fund investment in Series C - Translate Bio
Omega Funds
Omega Funds investment in Series C - Translate Bio
Monsanto Growth Ventures (MGV)
Monsanto Growth Ventures (MGV) investment in Series B - Translate Bio
Official Site Inspections
http://www.translate.bio
- Host name: ec2-54-247-151-159.eu-west-1.compute.amazonaws.com
- IP address: 54.247.151.159
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Translate Bio"
Sanofi to Buy Translate Bio, Expanding mRNA Tech | Sanofi
Aug 3, 2005 The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange … See details»
Sanofi swoops on partner Translate, buying the …
6 days ago Sanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together in 2018, and has now gone all in, offering $3.2 billion to buy the company outright. See details»
Translate Bio - AnnualReports.com
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by … See details»
Translate Bio 2025 Company Profile: Valuation, …
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases … See details»
Translate Bio - Crunchbase Company Profile
Translate Bio is a biotechnology company that in biotechnology, RNA therapeutics, and rare diseases. Translate Bio is a therapeutics company … See details»
Overview | Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, … See details»
Sanofi concludes acquisition of Translate Bio for …
Sep 15, 2021 With the acquisition, Translate Bio will continue as a surviving corporation and work as an indirect, fully owned unit of Sanofi. Sanofi and Translate Bio signed a partnership and exclusive licence agreement in … See details»
Translate Bio - VentureRadar
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. … See details»
Translate Bio Company Profile - Office Locations, Competitors
Translate Bio $138.81 m in annual revenue in FY 2020. See insights on Translate Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. See details»
Sanofi acquires Translate Bio for mRNA therapeutic …
Sep 24, 2021 Sanofi acquired all outstanding shares of Translate Bio for $38 per share in cash, representing a total equity value of approximately $3.2 billion on a fully diluted basis. Translate Bio is an mRNA therapeutics … See details»
Translate Bio - Leadership Team - The Org
The Leadership Team at Translate Bio is responsible for guiding the strategic direction of the company and ensuring the successful development and commercialization of RNA-based … See details»
Sanofi completes acquisition of Translate Bio, accelerating the ...
Sep 14, 2013 Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics . PARIS – September 14, 2021 - Sanofi announced … See details»
Translate Bio, Inc. Company Profile & Data: stocks, market cap ...
Jan 1, 2025 It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in … See details»
Translate Bio Buyout Shows Growing Hunger for mRNA Technology
Aug 17, 2021 Sanofi partnered with Translate Bio in 2018 to co-develop mRNA vaccines for infectious diseases and expanded the deal last year as the partners worked on mRNA Covid … See details»
Sanofi acquires Translate Bio - 2021-08-03 - Crunchbase
Aug 3, 2021 Translate Bio Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases. Acquiring Organization: Sanofi Sanofi is … See details»
Translate Bio Announces Key Leadership Additions and Promotions
LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of … See details»
Sanofi completes acquisition of Translate Bio, accelerating the ...
PARIS– September 14, 2021- Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’ s efforts to develop transformative vaccines … See details»
Translate Bio - Funding, Financials, Valuation & Investors
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases. New. Resources. Advanced Search. Start Free Trial . ... How much funding … See details»
Sanofi and Translate Bio expand collaboration to develop mRNA …
Jun 23, 2004 About the Sanofi Pasteur and Translate Bio collaboration In 2018, Translate Bio entered into a collaboration and exclusive license agreement with Sanofi Pasteur Inc., the … See details»
BIO 2025: Breakthroughs can't wait. | BIO - bio.org
2 days ago America’s leadership in biotech is essential to national security—and it’s under threat, said the National Security Commission on Emerging Biotechnology (NSCEB) in a BIO … See details»